Clinical Trials · NCT07018544
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
- Phase
- N/A
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 840
- Start date
- Nov 2024
- Locations
- 8 sites, South Korea
- Primary endpoint
- Number (incidence) of AEs